(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 February 2011 (03.02.2011)

PCT

(10) International Publication Number
WO 2011/013034 A4

(51) **International Patent Classification**:
A61K 39/00 (2006.01) ***C07K 14/47*** (2006.01)

(21) **International Application Number**:
PCT/IB2010/053313

(22) **International Filing Date**:
20 July 2010 (20.07.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/229,860 30 July 2009 (30.07.2009) US

(71) **Applicant** *(for all designated States except US)*: **PFIZER VACCINES LLC** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **SMITH III, George, Joseph** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, California 92121 (US). **WILLS, Kenneth, Nelson** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, California 92121 (US). **ZHU, Jeff, Xianchao** [US/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, California 92121 (US).

(74) **Agent**: **BENSON, Gregg, C.**; Pfizer Inc. Eastern Point Road MS9114, Groton, Connecticut 06340 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*

— *with sequence listing part of description (Rule 5.2(a))*

Date of publication of the amended claims: 28 April 2011

(54) **Title**: ANTIGENIC TAU PEPTIDES AND USES THEREOF

(57) **Abstract**: The present disclosure relates to immunogens and compositions comprising an antigenic tau peptide, preferably linked to an immunogenic carrier for use in the treatment of tau-related neurological disorders. The disclosure further relates to methods for production of these immunogens and compositions and their use in medicine.

WO 2011/013034 A4